- Went public, Jun 2007
- Raised $5.5M funding round, Aug 2024
- Raised $8.5M funding round, Jul 2023
About
Evogene is a computational biology company focused on revolutionizing product discovery and development in multiple life sciences-based industries, including human health and agriculture, through the use of its broadly applicable computational predictive biology (CPB) platform.
The CPB platform, incorporating a deep understanding of biology leveraged through the power of big data and artificial intelligence, has been designed to computationally discover and guide the development of life sciences products based on microbes, small molecules, and genetic elements.
Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd, medical cannabis through Canonic Ltd, agricultural biologicals through Lavie Bio Ltd, agriculture chemicals through AgPlenus Ltd, and agriculture solutions for castor oil production through Castera Ltd.
Funding history · 8 rounds · $135.7M total
Q&A
- What was a significant recent collaboration announced by Evogene?
- In October 2024, Evogene announced a collaboration with Google Cloud to develop a generative AI foundation model for novel small molecule design.
- What is the latest development regarding Evogene's subsidiary, Casterra, in Africa?
- In October 2024, Casterra announced a key milestone in its operational expansion plan in Africa, completing the first shipment of castor seeds grown and processed in Kenya.
- What is the status of Lavie Bio's bio-fungicide program against Downy Mildew?
- In November 2024, Lavie Bio advanced its bio-fungicide LAV321, targeting Downy Mildew, to the pre-commercial stage following successful 2024 field trial results.
- What is the latest commercial expansion for Lavie Bio's Yalos™ bio-inoculant?
- In November 2024, Lavie Bio announced the commercial expansion of Yalos® as a seed-treatment for soybean, following successful field trials.
- What is the latest news on Evogene's collaboration with Watershed AC and Ben-Gurion University?
- In October 2024, Watershed AC, Evogene, and Ben-Gurion University received approval for a second-year grant to continue their collaboration focused on improving crustacean traits using gene editing technology.
- What is the recent development concerning Evogene's subsidiary, Biomica, and its immuno-oncology drug?
- In January 2024, Biomica successfully completed Phase I trial enrollment for its microbiome-based immuno-oncology drug.
- What is the recent collaboration Evogene entered into to advance probiotic innovation?
- In February 2024, Evogene and Verb Biotics entered a collaboration agreement to advance probiotic innovation.
- What is the recent licensing and collaboration agreement for Evogene's subsidiary AgPlenus?
- In February 2024, AgPlenus announced a licensing and collaboration agreement with Bayer to develop a new sustainable weed control solution.
- What is the recent commercial expansion of Lavie Bio's Yalos™?
- In July 2024, Lavie Bio announced the commercial expansion of Yalos™ to winter wheat.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | evogene.com |
|---|---|
| linkedin.com/company/100603 | |
| facebook.com/evogene123 |
Identifiers & details
| Founded | 2002-1 |
|---|---|
| Employees (exact) | 110 |
| Offices | Rehovot |
| Market cap | $9.3M |
| Status reason | Public on TASE on Jun, 2007;Public on NASDAQ on Nov, 2013; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2007-06 | $8.0M | |||
| 2013-11 | $74.0M |